Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Revolution Medicines (RVMD) shares advanced over 12% following positive Phase 1 trial updates for its drug Daraxonrasib, particularly in pancreatic ductal adenocarcinoma (PDAC). Key data highlights include a 35% objective response rate (ORR) and 92% disease control rate (DCR) with median overall survival exceeding 13 months in second-line RAS mutant PDAC, alongside a 47% ORR in first-line monotherapy and 55% with combination therapy. The consistent safety profile and progression towards Phase 3 trials, including an expected 2026 data readout for RASolute 302 and a new Phase 3 trial initiation in Q4 2025, prompted multiple analysts to maintain positive ratings and raise price targets.

Analysis

Revolution Medicines (RVMD) has presented compelling early-stage clinical data for its lead asset, daraxonrasib, significantly de-risking its development path in pancreatic ductal adenocarcinoma (PDAC). In the second-line setting for RAS mutant PDAC, the drug demonstrated a confirmed objective response rate (ORR) of 35% and a disease control rate (DCR) of 92%, with a notable median overall survival (OS) of 13.1 months. These results are supported by a consistent and well-tolerated safety profile. The company's pipeline progression is clear, with its RASolute 302 Phase 3 trial on track to complete enrollment this year, setting up a pivotal data readout in 2026. Furthermore, initial first-line monotherapy data is even more promising, showing a 47% ORR, which increases to 55% when combined with gemcitabine nab-paclitaxel. While longer follow-up is required to confirm durability, these early signals prompted the company to plan a new Phase 3 trial (RASolute 303) for Q4 2025. The market and analysts have validated the data's significance, reflected in a 12.34% stock increase and multiple price target raises from firms including Wells Fargo (to $70) and Wedbush (to $77).

Key Decisions for Investors

• The positive Phase 1 data across both first- and second-line PDAC settings represents a significant clinical de-risking event, supporting a bullish stance on daraxonrasib's potential, but investors should monitor upcoming data for durability of response.
• Investors should mark their calendars for key catalysts that could drive future valuation, including the completion of Phase 3 enrollment for RASolute 302 this year, the full data readout expected in 2026, and the initiation of the RASolute 303 trial in Q4 2025.
• Given the stock's 12.34% rally, investors should assess the current valuation relative to the newly raised analyst price targets of $66-$77, which suggests further upside but also accounts for future successful clinical execution, the primary remaining risk.